Antibody-cytokine fusion proteins for the therapy of cancer

Journal of Immunological Methods

Volumn 248, Issue 1-2, 2001, Pages 91-101

  Penichet, Manuel L ^a   Morrison, Sherie L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibodies; Antibody fusion protein; Cancer; Cytokines; Immunocytokine; Immunotherapy

Indexed keywords

ANTIBODY; COLONY STIMULATING FACTOR 1; CYTOKINE; DANSYL CHLORIDE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN IDIOTYPE; INTERLEUKIN 12; INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER THERAPY; CONTROLLED STUDY; DRUG EFFECT; GENETIC ENGINEERING; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LYMPHATIC LEUKEMIA; MOUSE; MULTIPLE MYELOMA; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR CELL LINE; TUMOR GROWTH; TUMOR LOCALIZATION;

ANIMALS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-12; INTERLEUKIN-2; MICE; NEOPLASMS; RECOMBINANT FUSION PROTEINS;

ANIMALIA;

EID: 0035251612     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(00)00345-8     Document Type: Review

References (82)

1. Human recombinant granulocyte-macrophage colony-stimulating factor increases cell-to-cell adhesion and surface expression of adhesion-promoting surface glycoproteins on mature granulocytes
2. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy
3. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response
4. Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy
5. Differential modulation of surface antigens on human macrophages by IFN-gamma and GM-CSF: Effect on susceptibility to LAK lysis
6. A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway
7. Clinical trials - IL-12 deaths - Explanation and a puzzle
8. Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically
9. Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies
10. IL-2-activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayers. Implications for vascular leak syndrome
11. The fate of interleukin-2 after in vivo administration
12. Soluble and cell-associated transferrin receptor in lung cancer
13. Gene transfer as cancer therapy
14. Recombinant immunocytokines targeting the mouse transferrin receptor: Construction and biological activities
15. The molecular cell biology of interferon-gamma and its receptor
16. Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function
17. Local administration of interleukin-2 activates lymphocytes from tumor bearing mice to recruit host immunoreactivity and inhibit tumor growth
18. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo
19. Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases
20. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor
21. Interleukin-12 induces interferon-gamma-dependent switching of IgG alloantibody subclass
22. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes
23. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor
24. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2
25. In vivo properties of an IgG3-IL-2 fusion protein. A general strategy for immune potentiation
26. An IgG3-IL2 fusion protein activates complement, binds Fc gamma RI, generates LAK activity and shows enhanced binding to the high affinity IL2-R
27. An IgG3-IL-2 fusion protein has higher affinity than hrIL-2 for the IL-2R alpha subunit: Real time measurement of ligand binding
28. Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells
29. Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties
30. Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors
31. Gene therapy for prostate cancer
32. Development of Th1 Cd4+ T-cells through IL-12 produced by listeria-induced macrophages
33. A chimeric Lym-1/interleukin 2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake
34. Gene therapy of metastatic cancer by in vivo retroviral gene targeting
35. Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model
36. An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plusfree recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production
37. Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo
38. Treatment of B-cell lymphoma with chimeric IgG and single-chain Fv antibody-interleukin-2 fusion proteins
39. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy
40. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor
41. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2
42. Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin 2
43. Interleukin-2 in cancer treatment: Disappointing or (still) promising? A review
44. Intratumoral low-dose interleukin-2 induces rejection of distant solid tumour
45. Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: Three consecutive stages may be required for successful tumor vaccination
46. Polyethylene-glycol-modified interleukin-2 is superior to interleukin-2 in locoregional immunotherapy of established guinea-pig tumors
47. Bifunctional fusion between nerve growth factor and a transferrin receptor antibody
48. Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells
49. Interleukin 2 induced leukocyte adhesion to the normal and tumor microvascular endothelium in vivo and its inhibition by dextran sulfate: Implications for vascular leak syndrome
50. Development of an assay to detect an anti-hu14.18-I12 response following in vivo therapy with anti-GD2 fusion protein, hu14.18-I12
51. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity
52. In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice
53. An IgG3-IL-2 fusion protein recognizing a murine B cell lymphoma exhibits effective tumor imaging and antitumor activity
54. Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: Implication for gene therapy with adenovirus vectors
55. Tumour regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Preliminary report
56. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: Identification of the antigens mediating response
57. Granulocyte-macrophage colony-stimulating factor: Pleiotropic cytokine with potential clinical usefulness
58. Local interleukin-2 therapy in bovine ocular squamous cell carcinoma. A pilot study
59. Amplification of IL-2-driven T cell proliferation by recombinant human IL-3 and granulocyte-macrophage colony-stimulating factor
60. Cancer vaccines: The interleukin 2 dosage effect
61. Interleukin-2 toxicity
62. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer
63. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
64. Granulocyte-macrophage colony-stimulating factor stimulates human monocyte accessory cell function
65. Hepatocyte-directed gene delivery by receptor-mediated endocytosis
66. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma
67. Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: A phase Ib trial
68. Breast cancer gene therapy: Transgenic immunotherapy
69. Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease
70. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region
71. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity
72. IL-12 induces T helper 1-directed antitumor response
73. Inhibition of angiogenesis in vivo by interleukin 12
74. Effect of cloned interferon-gamma on expression of H-2 and Ia antigens on cell lines of hemopoietic, lymphoid, epithelial, fibroblastic and neuronal origin
75. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy
76. T cell memory against colon carcinoma is long-lived in the absence of antigen
77. Comparison of the effects of IL-3, granulocyte-macrophage colony-stimulating factor, and macrophage colony-stimulating factor in supporting monocyte differentiation in culture. Analysis of macrophage antibody-dependent cellular cytotoxicity
78. In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors
79. Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters
80. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts
81. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: Response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells